World ranking of pharmaceutical companies. Pharmaceutical world market Top pharmaceutical companies

AstraZeneca is a leading international innovative biopharmaceutical company engaged in the research, development, production and sale of medicines.

AstraZeneca is one of the ten leading pharmaceutical companies in the world and owns 29 factories in 20 countries.

Three strategic research centers (Cambridge, UK; Gaithersburg, MD, USA; Gothenburg, Sweden) are located close to global life sciences clusters, allowing for the full potential of collaboration with outstanding scientists and leading scientific organizations.

The company's portfolio includes drugs from such therapeutic areas as cardiology, pulmonology, oncology, neurology, psychiatry, infectious diseases, vascular pathology and gastroenterology.

The company has recently focused on innovation in three key therapeutic areas: cardiovascular and metabolic diseases, oncology, and respiratory, inflammatory and autoimmune diseases.

AstraZeneca continued active research in the fields of neurology and gastroenterology.

Active development is underway in the areas of biologics, small molecules, immunotherapy, protein engineering and drug delivery devices.

Bristol-Myers Squibb Co is one of the largest American pharmaceutical companies that produces and distributes drugs and medications against cancer, HIV infection, analgesics, antibiotics and cardiac drugs.

Lilly is a leading innovative pharmaceutical corporation founded in 1876. The Corporation develops and markets innovative medicines aimed at effectively treating a range of diseases, primarily in the fields of endocrinology, oncology, psychiatry, infectious diseases, neurology, cardiology and urology.

The company employs more than 38,000 people worldwide. The company conducts clinical trials in 50 countries, has research laboratories in 8 countries, and production facilities in 13 countries. The corporation's products are sold in 125 countries.

British pharmaceutical company, one of the largest in the world. Headquarters are in Brentford, a suburb of London. The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

The main production facilities are concentrated in the UK, Spain, Ireland, USA and Singapore. The main sales come from drugs in therapeutic areas: respiratory diseases, oncology, HIV/AIDS, diabetes, mental disorders, prevention of infectious diseases (vaccines for various age groups).

Johnson & Johnson is the world's largest manufacturer of human health products, pharmaceuticals and medical devices. In Russia and the CIS countries, Johnson & Johnson products have been represented in three areas since 1992: consumer products, products for hospitals, and pharmaceutical products.

The pharmaceutical division is represented by the Janssen group of companies, whose research includes oncology (including multiple myeloma and prostate cancer), immunology (psoriasis), psychiatry (schizophrenia, Alzheimer's disease), infectious diseases (HIV/AIDS, hepatitis C and tuberculosis) , as well as cardiovascular diseases and metabolic disorders (diabetes).

Today, MSD is one of the world's leading healthcare providers, providing consumers with medicines, vaccines, biologic therapies, general medical products and veterinary products.

The company does business in more than 140 countries, introducing innovative solutions to maintain and restore health. MSD's drug portfolio and core research focuses on treating and preventing diseases that pose major threats to public health: infectious diseases, cardiovascular diseases, diabetes, women's health and respiratory diseases.

Novartis is a transnational pharmaceutical corporation, currently consisting of six business divisions: Pharma (innovative prescription drugs), Alcon (full range of vision care products), Sandoz (high-quality generics and biosimilars), OTC (over-the-counter products), Vaccines and Diagnostics (vaccines and test systems), Animal Health (medicines for animals).

The main areas of research and development of Novartis (Novartis) are oncology, cardiovascular diseases, ophthalmology, neurology, and biological drugs.

The company is also developing innovative areas such as immuno-oncology, aging prevention, regenerative medicine and infectious diseases.

The headquarters is located in Basel, Switzerland. The company employs approximately 120,000 employees in more than 140 countries.

The representative office of Novartis in Ukraine was opened in 1993.

The company was founded in 1896 in Basel, Switzerland, and today has offices in 150 countries and employs more than 80,000 people. As one of the leading manufacturers of original drugs in the field of oncology, virology and transplantology, the company pays special attention to the issues of combining the effectiveness of its drugs with the convenience and safety of their use.

In addition to the company F. Hoffmann - La Roche, the Roche group includes Genentech, USA and Chugai, Japan. Roche's activities in Ukraine began in 1998 with the establishment of a Representative Office. In 2009, Roche Ukraine LLC was registered.

Sanofi is a diversified pharmaceutical company. Its divisions operate in more than 100 countries around the world. Sanofi's subsidiaries are the following companies: Sanofi Pasteur – production of vaccines; Genzyme is an innovative biotechnology company; Chattem – production of over-the-counter drugs; Merial – production of veterinary drugs; Zentiva – production of generics.

Main areas of work: emerging markets; diabetes; vaccines; health products; innovative products; animal health.

Teva Ukraine LLC is part of TEVA Corporation, a leading international pharmaceutical company specializing in the development, production and marketing of generic and original medicines, as well as active pharmaceutical ingredients.

The company began operating in Ukraine in 1997 and is now one of the top three leaders in the Ukrainian pharmaceutical market. Today about 400 employees work here.

The company's activities in Ukraine are concentrated in the following areas of medicine:

• central nervous system diseases
• mental illness
• diseases of the respiratory system of both viral and bacterial etiology
• oncology
• diseases of the cardiovascular system
• women Health
• bone metabolism disorder
• diseases of the liver and gastrointestinal tract.

From humble beginnings in the production of fine chemicals, Pfizer has grown into a major pharmaceutical company and a leader in the global pharmaceutical market.

Pfizer is a leader in developing new drugs to treat diabetes, cancer and cardiovascular diseases. The company annually invests about $7.5 billion in research aimed at creating new effective drugs. The company operates in more than 150 countries around the world. Research centers are located in the UK (Sandwich) and the USA (Groton and New England, La Jolla, St. Louis, Rinat, Cambridge).

AbbVie is a global research and development biopharmaceutical company.

The company's activities are focused on the development of medications with a pronounced clinical effect, benefiting the patient and being cost-effective, especially in those areas where there is the greatest need for them, in particular in the treatment of hepatitis C, chronic kidney disease, neurology, immunology, oncology and women's health.

On December 19 in Moscow, the National Pharmaceutical Rating awarded the best manufacturers of medicines and medicinal cosmetics, as well as the most successful brands.

Selection of nominees built on objective indicators – sales volumes of pharmaceutical products. The rating is based on independent research and analytics by DSM Group.

Results of the “National Pharmaceutical Rating - 2017”:

• The company won in the Rx-manufacturer category, with Pfizer in second place and Pfizer in third.
• The company topped the OTC Manufacturer nomination "OTCPharm", followed by Bayer, and Johnson & Johnson closes the top three.
• In the “OTC-drug” category the first place is taken by "Kagocel", on the second - "Nurofen", on the third - "Ingavirin".
• The brand won the Rx-drug category "Prevenar 13", in second place is Revlimid, in third place is Kaletra.
• In the nomination “Rx-drug on the pharmacy market” the first place is taken by "Concor", on the second – “Actovegin”, on the third – “Xarelto”.
• In the nomination “Dietary Supplement Manufacturer”, the first place, as a year earlier, is taken by the company "Evalar", in second place is PharmaMed, and Solgar Vitamin and Herb closes the top three.
• First place in the category “Brand Dietary Supplements” Solgar, in second place is the brand “Doppelgerts”, in third place is “Vitamishki”.
• In the category "Cosmetics Manufacturer" in first place - L'Oréal, followed by the Zeldis-Pharma company, and Pierre Fabre closes the top three.
• In the “Cosmetics Brand” category – first place – Librederm, in second place is La Roche Posay, in third place is Vichy.
• In the “Toothpaste Brand” category, the leaders were distributed as follows: in first place R.O.C.S., on the second Lacalut, on the third Splat.
• Nomination “Wound care products and first aid. Manufacturer" was headed by the company Paul Hartmann, Johnson & Johnson is in second place, Veropharm is in third place.

“The purpose of the National Pharmaceutical Rating is to evaluate the results of work and identify leaders in terms of sales volume in Russia over the past year, recognize the best in the industry and deservedly reward those who provide the country with quality medicines and value the social component of their activities. This year’s ceremony is distinguished by an important charitable mission: along with summing up the results of the rating, we collected gifts for two orphanages and for the House of Stage Veterans named after. A. Yablochkina. Next week we will organize the transfer of all the gifts, and this will be another small but pleasant occasion in creating a New Year’s mood for everyone,” says the CEO of DSM Group Sergey Shulyak.

The awards ceremony for the nominees of the National Pharmaceutical Rating brought together more than 300 participants and guests, leading show business artists, the media, as well as top managers of pharmaceutical companies and industry associations. The award ceremony was celebrated in the Miх Afreparty hall with the energy of a real rock party, with drive and in a format unusual for official events.

Biopharmaceutical industry very dynamic. Big Pharma players in 2016 resorted to a variety of ways to increase income. Some of them relied on innovative drugs, while others were actively developing biosimilars - analogues of drugs of biological origin that had lost their exclusivity. Pharmaceutical companies have worked productively in many areas of medicine, but the development of advanced cellular and gene technologies, for example, in the field of immunological oncology and the treatment of neurodegenerative diseases, seems especially promising. To reorient industry priorities and implement development strategies, companies exchanged assets and expanded product portfolios. In this publication, you will be able to get acquainted with the top five leaders of the global pharmaceutical market in terms of sales income at the end of 2016, as well as the methods that helped companies achieve such great heights.

Not all Big Pharma players saw tangible benefits in 2016 in terms of increased sales revenue. 4 companies from the above five increased their sales income in 2016 compared to 2015 (table), but a significant increase in the indicator is typical only for Pfizer and Roche (8 and 5%, respectively). For Johnson & Johnson and Roche, the total sales revenue for all divisions is shown.

Source: “Top 15 pharma companies by 2016 revenue” report by FierceFarma.

To increase sales revenue, they are actively developing new drugs, looking for opportunities to acquire “successful” assets and ways to intensify the promotion of products on the market. Let's consider what strategic steps the companies from the above top 5 took in 2016.

"JOHNSON & JOHNSON"

The company is known for regularly adding new products to the global pharmaceutical market, while its shareholders can remain calm due to the stability of stock prices. Total sales revenue for all Johnson & Johnson divisions in 2016 was $71.9 billion. USA, and global sales of the company's pharmaceutical division are $33.5 billion. with a 6.5% increase in this indicator compared to 2015.

Blood cancer drug Imbruvica (ibrutinib) had a banner year in 2016, with sales of $1.2 billion, up 86% from 2015. It is a first-in-class Bruton's tyrosine kinase inhibitor. , which Johnson & Johnson released in collaboration with AbbVie. According to EvaluatePharma, the drug will be the third best-selling cancer blockbuster in the world in 2022, with projected sales revenue of $8.29 billion.

Johnson & Johnson certainly entered 2017 in better shape than it did in 2016. During that time, it made several important moves. The largest of these was a complex $30 billion deal that began negotiations in 2016 and ended in January 2017. Johnson & Johnson acquired Swiss biotech company Actelion Pharmaceutical Ltd. and for 280 dollars. per share received a Swiss biotech portfolio of promising drugs, including Opsumit (macitentan) and Uptravi (selexipag) - drugs for the treatment of pulmonary arterial hypertension. Once the deal is completed, the company expects to see rapid earnings growth from sales of these drugs, which generated more than $1 billion in revenue in 2016.

In the stock market, Johnson & Johnson continues to maintain high profitability. In 2016, the value of its shares increased by 12% compared to 2015. In terms of share price growth, the company ranked between GlaxoSmithKline (14%) and Merck & Co (11%). This provision is viewed as a “safe harbor” in a volatile pharmaceutical market.

Johnson & Johnson confidently promotes new products to the market thanks to the professional work of marketing specialists. Johnson & Johnson CEO Alex Gorsky said that in 2017, professional marketing will help achieve a 4-5% increase in profits compared to 2016. According to company experts, sales income in 2017 will be 74.1–74.8 billion dollars, and adjusted profit - 6.93–7.08 dollars. per share.

"PFIZER"

In 2016, an important event was to take place in the global pharmaceutical market - the merger of Pfizer Inc. and Allergan, but the deal was cancelled. Despite this, Pfizer reported higher profits in 2016 and is expanding its distribution footprint to maintain that growth.

Pfizer is strengthening its position in the global market: in 2016, its sales in monetary terms increased by 5% ($2.2 billion) compared to 2015 and reached $48.1 billion. In the United States, the increase in this indicator was more significant, sales income increased by 21% ($4.7 billion) over the specified period. A number of products played an important role in this: the breast cancer drug Ibrance (palbociclib), the antiepileptic drug Lyrica (pregabalin), the anticoagulant Eliquis (apixaban), the arthritis drug Xeljanz (tofacitinib) and the nicotine addiction drug Chantix (varenicline). . In total, during the period under review, the volume of their sales in monetary terms increased by more than $2.8 billion.

Palbociclib saw sales revenue soar from $723 million. in 2015 to 2.14 billion dollars. in 2016. The Company expects the product to become more profitable in the future as physicians prescribe it to a wider range of patients.

Meanwhile, apixaban has created excitement in the market for a new generation of anticoagulants. After a tepid start, Pfizer and its partner Bristol-Myers Squibb have invested heavily in marketing the drug, and the drug is now catching up to Johnson and Johnson's Xarelto (rivaroxaban) in terms of marketing investment.

In 2016, Pfizer was able to close several important deals that it believes will help increase revenue. In August, it acquired the company Medivation, which was a tasty morsel for many Big Pharma players. By entering into a purchase agreement, Pfizer acquired the rights to the prostate cancer drug Xtandi (enzalutamide).

Prior to this, Pfizer acquired Anacor Pharmaceuticals and secured the rights to the potential blockbuster eczema treatment Eucrisa (crisaborole), which was approved by US regulators in December 2016.

The company is not going to stop there. It plans to continue making acquisitions that will drive earnings growth, said Frank D'Amelio, the company's chief financial officer. And if the U.S. considers tax reforms affecting the flow of funds from abroad, Pfizer will have plenty of room to make such purchases.

"ROCHE"

Roche derives consistent revenue from a successful portfolio of oncology blockbusters such as Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab). Compared to 2015, the Swiss company's global sales revenue increased by 4% in 2016, and its net profit increased by 7% ($9.8 billion). The company's analysts calculated that sales growth will remain at this level in 2017. Chief Executive Officer Severin Schwan expects innovation to be the pharmaceutical manufacturer's main driving force in the future.

Roche's new products, such as Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine), are intended to treat aggressive metastatic breast cancer. The pharmaceutical company tested their combinations with time-tested drugs. If successful, this approach could stimulate sales of both older and newer drugs.

The combination of Herceptin and Perjeta increased revenue from sales of these products. In 2016, sales of the first drug in monetary terms increased by 4% (to $6.7 billion) compared to 2015, and the second by 26% (to $1.8 billion), which allowed it take 4th place in the ranking of Roche products in terms of sales income for 2016. For the drug Kadcyla, this figure increased by 7% (to $821 million) for the specified period.

Tecentriq (atezolizumab) from Roche is the company's first immuno-oncology product. The drug's revenue is expected to skyrocket in the near future as Tecentriq received U.S. Food and Drug Administration approval in October 2016 for the treatment of non-small cell lung cancer. The drug was previously approved for the treatment of urothelial carcinoma, the most common bladder cancer.

Roche launched four new drugs and nine diagnostic tests in 2016, and is expecting some key regulatory approvals in 2017, including the approval of Ocrevus (ocrelizumab), a potential multiple sclerosis drug that could be its biggest launch yet in 2017

"NOVARTIS"

In a massive $25 billion asset swap, Novartis sold its veterinary division (Novartis Animal Health) to Eli Lilly and its vaccine business to GlaxoSmithKline in exchange for some of the British drugmaker's oncology assets . The deals come as the Swiss company focuses primarily on cancer drugs. Novartis plays a critical role in the rapid development of the immunological oncology field. The company is focused on the next wave of drugs in this promising area and has a portfolio of drug candidates in development.

In the fall, Novartis achieved priority review for the LEE011 molecule. This substance is also known as ribociclib and could compete with Ibrance, Pfizer's famous oncology product. The analytical company EvaluatePharma considers ribociclib as a promising launch of the year, and its projected sales revenue in 2022 is estimated at $1.6 billion.

Novartis CEO Joe Jimenez says biosimilars will be a key driver of the company's revenue growth in the future. Approval is expected in August 2017 for a biosimilar to Amgen's tumor necrosis factor inhibitor Enbrel (etanercep). Novartis plans to launch biosimilars to Humira (adalimumab, AbbVie), Rituxan (rituximab, Biogen) and Remicade (infliximab, Johnson & Johnson) in the near future.

D. Jimenez also expects the company's revenue to increase thanks to new products such as Cosentyx (secukinamab), a drug for the treatment of psoriasis. It achieved blockbuster status in 2016, achieving sales of $1.1 billion.

Novartis is interested in conducting mergers and acquisitions worth up to $5 billion. and plans to actively continue activities in this area.

"MERCK & CO"

In 2016, Merkс & Co increased its revenues on the global market by 1% compared to 2015 and is optimistic about the future. For her, an important milestone was that in 2016 the drug Keytruda (pembrolizumab) received blockbuster status with sales revenue of $1.4 billion. - this is a big breakthrough compared to income of $566 million. in 2015. The drug competed with Opdivo (nivolumab), a product of Bristol-Myers Squibb.

Merkc & Co. has operated during a period of significant volatility and uncertainty, including the current political and regulatory environment in the United States, as CEO Ken Frazier told investors and company analysts at a conference in late 2016. However, he believes Big Pharma players will weather these uncertainties through their broad and balanced product offerings.

Merkс & Co became one of the leading pharmaceutical companies in terms of share price growth in 2016, second only to GlaxoSmithKline and Johnson & Johnson.

The company was able to increase worldwide sales revenue for Januvia (sitagliptin) in 2016 compared to 2015, an important win as intense competition among diabetes drugs has hurt some competitors' profits. During this period, Januvia's sales volume in monetary terms increased by 2%, reaching $6.1 billion.

The human papillomavirus vaccine Gardasil has become another successful product from Merkc & Co. The franchise led to a double increase in income from vaccine sales: in 2016, the figure increased to $2.17 billion.

Entering 2017, the company believes its profitability is improving, which will lead to higher net earnings per share. In 2016 in the USA this figure was 2.04 dollars, and its range in 2017 is calculated as 2.47–2.62 dollars.

After the announcement of financial results for 2016, Merkc & Co announced that its drug candidate for HIV therapy - doravirine - showed significant success in phase III clinical trials and, after entering the market, will be able to become a worthy competitor to the company's drug Prezista (darunavir). Johnson & Johnson.

RESULTS

Large ones have significant potential to balance in difficult conditions in the global market thanks to a wide product portfolio. In 2016, Big Pharma players placed bets on both proven and innovative drugs and the development of biosimilars, invested in the development of products in new areas of medicine, for example, immunological oncology, exchanged assets and replenished product portfolios in order to increase revenues from sales in the future.

Our top 10 pharmaceutical companies in Russia will tell you about a dozen famous Russian drug manufacturers.

10 Veropharm

9 NPO Petrovax Pharm

8 OZONE Pharmaceuticals

7 Valenta Farm

6 R-Pharm

5 Pharmstandard

4 Sotex

3 Akrikhin

2 Biocad

1 STADA

The largest Russian pharmaceutical companies earned from 15 billion rubles (PJSC Pharmstandard) to 182 billion rubles (JSC NPK Katren) in annual revenue at the end of 2015.

In the last two years, 2015 and 2016, the Russian pharmaceutical industry has shown significant growth - more than 20% in 2016, according to the Minister of Industry and Trade of the Russian Federation Denis Manturov.

At a briefing held at the Russian Ministry of Industry and Trade, Deputy Minister Sergei Tsyb said that the best evidence of the growth of the domestic pharmaceutical industry is that the American pharmaceutical giants are outraged: it is difficult for them to break into the Russian market, since they are being squeezed out by large pharmaceutical companies in Russia. We analyzed and prepared the Top 7 largest Russian pharmaceutical holdings by revenue for 2015.

Pharmstandard

Legal address: Moscow

Registration date: 1996

Founders: Minin Alexander Nikolaevich, Kuznetsov Igor Gennadievich.

CEO: Kuznetsov Igor Gennadievich

• Authorized capital: RUB 1,000,012.86.
• Fixed assets: 153,955 thousand rubles
• Revenue: 21,191,811
• Accounts receivable: 2,667,522 thousand rubles
• Accounts payable: 6,961,274 thousand rubles.
• Net profit: 1,042,833 thousand rubles
• Net assets: 2,646,595 thousand rubles
• INN - 7731241639

http://www.euro-service.ru/

Sia International

Joint Stock Company "Sia International LTD" is engaged in the sale of medicines and medical products to pharmacies and medical institutions.

It has warehouse complexes in Moscow and more than 35 cities of Russia. Their total area is more than 200 thousand square meters.

Legal address: Moscow city

Registration date: 1995

Founders: JSC "Rink", Rudinsky Igor Feliksovich.

CEO: Demkin Alexander Yurievich

• Authorized capital: 20,000,000 rubles
• Fixed assets: 5,624,687 thousand rubles.
• Revenue: 59,438,184 thousand rubles
• Accounts receivable: 13,597,841 thousand rubles.
• Accounts payable: 20,209,002 thousand rubles.
• Net profit: -3,111,114 thousand rubles
• Net assets: 2,908,224 thousand rubles
• TIN - 7714030099

Sources: official website: http://siamed.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

R-Pharm

Joint Stock Company "R-Pharm" specializes in high-tech medicines. Currently, the company is working towards large-scale investment projects.

It is creating a production base as part of the state strategy for the development of the Russian pharmaceutical industry until 2020.

Legal address: Moscow

Registration date: year 2001

Founders: Repik Alexey Evgenievich

CEO: Ignatiev Vasily Gennadievich

• Authorized capital: RUB 28,400.
• Fixed assets: 2,119,636 thousand rubles
• Revenue: 62,204,014 thousand rubles
• Accounts receivable: 13,435,674 thousand rubles.
• Accounts payable: 30,682,362 thousand rubles
• Net profit: 8,608,010 thousand rubles.
• Net assets: 24,205,818 thousand rubles
• INN - 7726311464

Sources of information: official website: http://r-pharm.com, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Growth

Closed joint stock company "Rosta". In total, the Rosta pharmaceutical group includes 4 companies: Rosta (engaged in the distribution of medicines), Rosta Marketing (trade marketing), Raduga Production (a plant for the production of solid medicines), United Pharmacy Chain, which includes the companies “Rainbow”, “First Aid”, “Ladushka”.

Legal address: Moscow region, city of Podolsk

Registration date: 2002

Founders: Joint Stock Company PJSC "Tampo", Mirilashvili Mikhail Mikhailovich, Panikashvili David Isaakovich, Tseytlin Oleg Yakovlevich, Strepetov Vadim Valentinovich, Shepel Boris Albertovich, Semenyuk Alexander Vasilievich, Konev Oleg Yurievich.

The president: Panikashvili David Isaakovich

• Authorized capital: 1,000,000 rubles
• Fixed assets: 621,356 thousand rubles
• Revenue:63,384,563 thousand rubles
• Accounts receivable: 18,293,282 thousand rubles.
• Accounts payable: 35,244,901 thousand rubles
• Net profit: 415,314 thousand rubles
• Net assets: 1,755,002 thousand rubles.
• INN - 7726320638

Sources: official website: http://www.rostagroup.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Protek

Closed joint stock company firm "Implementation Center "Protek". The Protek group of companies is engaged in the production, distribution and retail sale of medicines through pharmacy chains.

The holding's production and technological capacities comply with GMP standards.

Legal address: Moscow

Registration date: 1994

Founders: JSC "Protek"

CEO: Pogrebinsky Dmitry Borisovich

• Authorized capital: 40,000,000 rubles
• Fixed assets: 1,082,865 thousand rubles.
• Revenue: 166,578,310 thousand rubles
• Accounts receivable: 32,742,113 thousand rubles.
• Accounts payable: 69,059,867 thousand rubles
• Net profit: RUB 5,419,719.
• Net assets: 8,094,159 rubles
• INN - 7724053916

Sources of information: official website of the company: http://www.protek-group.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).

Quatrain

The geography of Katren's work covers 85 constituent entities of the Russian Federation and delivers more than 18 thousand types of pharmaceutical products.

Legal address: city ​​Novosibirsk

Registration date: 1993

Founders: Konobeev Leonid Valentinovich, Spiridonov Vladimir Nikolaevich

CEO: Konobeev Leonid Valentinovich

• Authorized capital: 1 billion 500 million rubles
• Fixed assets: 6,752,880 thousand rubles
• Revenue: 182,301,551 thousand rubles
• Accounts receivable: 30,155,368 thousand rubles.
• Accounts payable: 65,656,588 thousand rubles
• Net profit: 5,790,742 thousand rubles
• Net assets: 11,103,940 thousand rubles.
• INN - 5408130693

Sources: official website: http://katren.ru, extract from the Unified State Register of Legal Entities, Rosstat (financial reporting data according to RAS for 2015).